Table 1.
Detailed information on the data used in Mendelian randomization analysis
| Traits | Data sources | Sample size(cases/controls) | Population | Use |
|---|---|---|---|---|
| IBD | de Lange et al. [24] | 59,957(25,042/34,915) | European | Exposure/Outcome |
| CD | 40,266(12,194/28,072) | |||
| UC | 45,975(12,366/33,609) | |||
| IBD (val) | Liu et al. [25] | 34,652(12,882/21,770) | European | Exposure for validation |
| CD (val) | 20,883(5956/14,927) | |||
| UC (val) | 27,432(6968/20,464) | |||
| KSD | FinnGen | 218,414(4969/213,445) | European | Outcome/Exposure |
| HDL-C | UK Biobank [34] | 403,943 | European | Confounders for MVMR analyses |
| LDL-C | 440,546 | |||
| TG | 441,016 | |||
| BMI | Hoffmann et al. [33] | 315,347 | European | Confounder for MVMR analysis |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; KSD, kidney stone disease; val, validation; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BMI, body mass index; MVMR, multivariable Mendelian randomization; FinnGen, FinnGen consortium; UK Biobank, UK Biobank consortium